BioMarin Goes Shopping

Shares of BioMarin Pharmaceutical (NASDAQ: BMRN  ) are up more than 40% in the last 12 months, and lately all eyes have been on its experimental Morquio syndrome drug. However, today the orphan drugmaker announced a $10 million deal to acquire Zacharon PharmaceuticalsIn this video, our health care analyst discusses this news and touches on last year's success of some prominent orphan drug companies, including NPS Pharmaceuticals (NASDAQ: NPSP  ) and Sarepta (NASDAQ: SRPT  ) .

BioMarin has been a longtime pick of The Motley Fool's Rule Breakers newsletter, and its shares are up more than 180% since it was recommended. If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2182917, ~/Articles/ArticleHandler.aspx, 8/29/2014 4:20:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement